Aktis Oncology, Inc. (AKTS) vs Castle Biosciences, Inc. (CSTL)
A side-by-side comparison of Aktis Oncology, Inc. and Castle Biosciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.13HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
CSTL
Castle Biosciences, Inc.
$34.03HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
Total return — AKTS vs CSTL
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)CSTL -6.8% (-6.8%/yr)CSTL compounded faster over this window
AKTS CSTL
AKTS vs CSTL: by the numbers
- •CSTL is the larger company ($1.04B vs $968M market cap).
- •Both run net losses; CSTL's is the smaller (-5.43% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | CSTL |
|---|---|---|
| P/S ratio | 96.25 | 2.91 |
| P/B ratio | 2.00 | 2.21 |
Profitability
| Metric | AKTS | CSTL |
|---|---|---|
| Gross margin | 100.00% | 77.26% |
| Operating margin | -1149.52% | -8.99% |
| Net margin | -727.04% | -5.43% |
| ROE | -15.09% | -4.13% |
| ROIC | -16.54% | -6.33% |
Growth (annualized)
| Metric | AKTS | CSTL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 35.55% |
| Total return CAGR (5Y) | N/A | -10.28% |
Go deeper
Dig into the metrics
Aktis Oncology ROECastle Biosciences ROEAktis Oncology operating marginCastle Biosciences operating marginAktis Oncology revenue growthCastle Biosciences revenue growthAktis Oncology free cash flowCastle Biosciences free cash flow
Aktis Oncology & Castle Biosciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.